TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35103237

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ACB with 14 ml 0.25% levobupivacaine and 100 mcg clonidine
Number of subjects: 77
Study: 32389236

Group type: EXPERIMENTAL
Intervention: Voice rehabilitation post-radiotherapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Irradiated control group
Number of subjects: 74
Study: 36180878

Group type: EXPERIMENTAL
Intervention: Scoliosis group (intervention)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lumbar disc herniation group (control)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 34167279

Group type: EXPERIMENTAL
Intervention: ASL
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: TOF MRA
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of ASL and TOF MRA
Number of subjects: 39
Study: 35138259

Group type: EXPERIMENTAL
Intervention: Unguided internet-based cognitive behavioral therapy (ICBT) for 4 weeks
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Three Good Things (TGT) exercise for 4 weeks
Number of subjects: 312

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ICBT
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: TGT
Number of subjects: 312
Study: 34065178

Group type: EXPERIMENTAL
Intervention: Tai Chi-based stroke rehabilitation program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Stroke-symptom management program
Number of subjects: 34
Study: 33384890

Group type: EXPERIMENTAL
Intervention: Multicolor scanning laser ophthalmoscopy (MC‐SLO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Color fundus photography (CFP)
Number of subjects: 40
Study: 33801969

Group type: EXPERIMENTAL
Intervention: Conventional treatment + virtual reality
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 43
Study: 34338615

Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 97

Group type: COMPARATOR
Intervention: Light smokers
Number of subjects: 97

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 97
Study: 32646519

Group type: EXPERIMENTAL
Intervention: Pre-hospital care capacity assessment
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Emergency response capabilities
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Emergency medical services policy
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Functional emergency response systems
Number of subjects: 163
Study: 34112520

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg twice daily
Number of subjects: 8144

Group type: EXPERIMENTAL
Intervention: Bupropion sustained-release 150 mg twice daily
Number of subjects: 8144

Group type: COMPARATOR
Intervention: Nicotine patch 21 mg once daily
Number of subjects: 8144
Study: 33135436

Group type: EXPERIMENTAL
Intervention: Single preoperative dose of 20 mg dexamethasone and a postoperative saline injection (Group B)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Two perioperative doses of 10 mg dexamethasone (Group C)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Two perioperative saline injections (Group A, placebo)
Number of subjects: 165
Study: 33774503

Group type: EXPERIMENTAL
Intervention: Dual-task training involving auditory-vocal and visual-manual tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-task performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-task performance
Number of subjects: 0
Study: 36121791

Group type: EXPERIMENTAL
Intervention: MegaShield®
Number of subjects: 140

Group type: COMPARATOR
Intervention: Guardix‐SG®
Number of subjects: 140
Study: 33762645

Group type: EXPERIMENTAL
Intervention: Gluma
Number of subjects: 55

Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 55

Group type: COMPARATOR
Intervention: Tetric N‐Bond self‐etch system
Number of subjects: 55
Study: 35656469

Group type: EXPERIMENTAL
Intervention: Persian medicine diet combined with Western medicine-based diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Western medicine-based diet
Number of subjects: 20
Study: 34034359

Group type: EXPERIMENTAL
Intervention: Health workers training to promote healthy feeding practices
Number of subjects: 20
Study: 33570497

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) technology
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: High users of IVR (received >75% of reminders)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Moderate use of IVR (51%-75%)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: IVR technology
Number of subjects: 600
Study: 35550486

Group type: EXPERIMENTAL
Intervention: Doubling usual standing time (60 minutes five times per week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Usual standing time (30 minutes three times per week)
Number of subjects: 25
Study: 34702015

Group type: EXPERIMENTAL
Intervention: Winning algorithm (3D-UNet model)
Number of subjects: 243

Group type: COMPARATOR
Intervention: 2nd to 5th place ensemble solutions
Number of subjects: 243
Study: 32381052

Group type: EXPERIMENTAL
Intervention: Healthy Habits Plus telephone-based program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time2bHealthy online program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group receiving written materials
Number of subjects: 0
Study: 34706071

Group type: EXPERIMENTAL
Intervention: Nurse-led intervention program based on a cognitive-behavioral approach
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 34897973

Group type: EXPERIMENTAL
Intervention: Students' education (4 sessions of 60 minutes)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Mothers' education (2 sessions of 90 minutes)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 261
Study: 34919862

Group type: EXPERIMENTAL
Intervention: Universal HIV testing and treatment (annual HIV and multidisease testing, universal ART eligibility, patient-centred care)
Number of subjects: 8198

Group type: COMPARATOR
Intervention: Control (baseline testing and medical care according to national guidelines)
Number of subjects: 8198
Study: 32434067

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (OIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33874981

Group type: EXPERIMENTAL
Intervention: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin) at 120mg/kg of body weight for 4 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin) at 120mg/kg of body weight (single dose) followed by 0.9% sodium chloride for 3 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0.9% sodium chloride intravenously once per week for four weeks (placebo)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intravenous Prolastin® (plasma‐purified alpha‐1 antitrypsin)
Number of subjects: 36
Study: 33333987

Group type: EXPERIMENTAL
Intervention: Eccentric single-leg decline squat exercise (SLDSe) with 6 s execution time (EG1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eccentric single-leg decline squat exercise (SLDSe) with 3 s execution time (EG2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eccentric single-leg decline squat exercise (SLDSe) (EG1 and EG2)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 36
Study: 35551299

Group type: EXPERIMENTAL
Intervention: Vistusertib (125 mg twice daily for 2 days per week) + Anastrozole (1 mg daily)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Anastrozole (1 mg daily)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vistusertib + Anastrozole
Number of subjects: 75

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 75
Study: 34740331

Group type: EXPERIMENTAL
Intervention: NGS (Next Generation Sequencing)
Number of subjects: 960

Group type: COMPARATOR
Intervention: No NGS (standard care)
Number of subjects: 960
Study: 35933686

Group type: EXPERIMENTAL
Intervention: Foster Care Intervention (FCG)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Caregiving quality in foster care at 42 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 68

Group type: COMPARATOR
Intervention: Never-institutionalized group
Number of subjects: 68
Study: 33420936

Group type: EXPERIMENTAL
Intervention: Prevent-Teach-Reinforce-for-Young-Children (PTR-YC) program
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Implementation fidelity and treatment acceptability
Number of subjects: 35
Study: 32396257

Group type: EXPERIMENTAL
Intervention: Ropinirole patch (up to 64 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ropinirole extended-release tablet (up to 16 mg/d)
Number of subjects: 0
Study: 34408046

Group type: EXPERIMENTAL
Intervention: Respiratory multiplex PCR and procalcitonin (experimental strategy)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Conventional microbiological investigations (usual strategy)
Number of subjects: 450
Study: 32404133

Group type: EXPERIMENTAL
Intervention: I'M FINE intervention (individualized aerobic exercise and coaching)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: I'M FINE intervention
Number of subjects: 90
Study: 35731062

Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A (BTX-A) nerve block
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study: 32783351

Group type: EXPERIMENTAL
Intervention: Canakinumab 2 mg/kg every 4 weeks (arm 1)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Canakinumab 4 mg/kg every 8 weeks (arm 2)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Canakinumab (discontinued)
Number of subjects: 182
Study: 33855222

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily (qd) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg qd at Week 12
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo at Week 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teneligliptin
Number of subjects: 0
Study: 32623087

Group type: EXPERIMENTAL
Intervention: IRIS group (n=82)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Non-IRIS group (n=210)
Number of subjects: 292
Study: 35555002

Group type: EXPERIMENTAL
Intervention: VR Oculus Quest 2TM headset
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AlioscopyTM autostereoscopic screen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3D-printed physical model
Number of subjects: 0
Study: 34864802

Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (61 patients)
Number of subjects: 160

Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser treatment (62 patients)
Number of subjects: 160
Study: 32692971

Group type: EXPERIMENTAL
Intervention: Medial MAT
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lateral MAT
Number of subjects: 31
Study: 34998276

Group type: EXPERIMENTAL
Intervention: ECAP-controlled, closed-loop SCS
Number of subjects: 134

Group type: COMPARATOR
Intervention: Fixed-output, open-loop SCS
Number of subjects: 134
Study: 35927676

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) 90 mg/kg/day plus standard of care (SOC)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (2-DG) 90 mg/kg/day plus SOC
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 110
Study: 35381407

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of nadroparin 3800 IU over 4 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration of nadroparin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subcutaneous (SC) administration
Number of subjects: 60
Study: 34313803

Group type: EXPERIMENTAL
Intervention: Alcohol beverage (M BAC ≈ 0.08%)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 81
Study: 32658497

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss (BWL)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Migraine education (ME)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both BWL and ME
Number of subjects: 110
Study: 35887855

Group type: COMPARATOR
Intervention: BoNT injections alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BoNT injections with OA therapy
Number of subjects: 0
Study: 36424485

Group type: EXPERIMENTAL
Intervention: MARF + PRF membrane
Number of subjects: 10

Group type: COMPARATOR
Intervention: MARF only
Number of subjects: 10
Study: 33648546

Group type: EXPERIMENTAL
Intervention: EPA and DHA (600 mg EPA and 260 mg DHA per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study: 34794973

Group type: EXPERIMENTAL
Intervention: CGM + DSS
Number of subjects: 80

Group type: COMPARATOR
Intervention: CGM
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (CGM + DSS and CGM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: DSS
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Active DSS users
Number of subjects: 80
Study: 33893213

Group type: EXPERIMENTAL
Intervention: I-PASS handoff bundle (Spanish version) including written and verbal handoff, teamwork training, advertising campaign, simulation exercises, observation, and standardized feedback.
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: I-PASS handoff bundle (Spanish version)
Number of subjects: 1465
Study: 32915891

Group type: EXPERIMENTAL
Intervention: 2 minutes of additional low intensity exercise (n = 47)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Stopping at peak exertion (n = 45)
Number of subjects: 92
Study: 35471896

Group type: EXPERIMENTAL
Intervention: Text intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of text and video interventions
Number of subjects: 0
Study: 33847344

Group type: EXPERIMENTAL
Intervention: 200 g cod fillet twice weekly for 16 weeks
Number of subjects: 133
Study: 33417682

Group type: EXPERIMENTAL
Intervention: Canakinumab (anti-inflammatory therapy)
Number of subjects: 60087

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60087

Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 60087

Group type: COMPARATOR
Intervention: Bococizumab
Number of subjects: 60087

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 60087

Group type: EXPERIMENTAL
Intervention: NLR quartiles
Number of subjects: 60087
Study: 36235775

Group type: EXPERIMENTAL
Intervention: High-Fat Diet (HFD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-Carbohydrate Diet (HCD)
Number of subjects: 15
Study: 33851734

Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance-based treatment (MABT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 44
Study: 36179950

Group type: EXPERIMENTAL
Intervention: Oral factor Xa inhibitors (apixaban, betrixaban, rivaroxaban)
Number of subjects: 97578

Group type: COMPARATOR
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 97578

Group type: COMPARATOR
Intervention: Oral factor Xa inhibitors
Number of subjects: 97578
Study: 33410564

Group type: EXPERIMENTAL
Intervention: Fully covered self-expandable metal stents (FCSEMS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Plastic stents (PS)
Number of subjects: 22
Study: 35816916

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral prevention program (matched)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Interpersonal prevention program (mismatched)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (equivalent rates of anxiety disorders)
Number of subjects: 98
Study: 34283917

Group type: EXPERIMENTAL
Intervention: Multicomponent psychological intervention administered through an interactive multimedia online videogame with a complementary smartphone app
Number of subjects: 25
Study: 33085033

Group type: EXPERIMENTAL
Intervention: JNJ‐55920839 10 mg/kg IV 6 times biweekly in subjects with SLE
Number of subjects: 74

Group type: COMPARATOR
Intervention: JNJ‐55920839 (various doses between 0.3 and 15 mg/kg IV or 1 mg/kg SC) in healthy subjects
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: JNJ‐55920839 (10 mg/kg IV) in subjects with SLE
Number of subjects: 74

Group type: COMPARATOR
Intervention: JNJ‐55920839 (various doses) in healthy subjects
Number of subjects: 74
Study: 35113224

Group type: EXPERIMENTAL
Intervention: Ranking-down (RD) group starting with a very strong corticosteroid, ranked down every 2 weeks unless FAfE exacerbated
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranking-up (RU) group starting with a weak corticosteroid, ranked up at exacerbation
Number of subjects: 0
Study: 34486662

Group type: EXPERIMENTAL
Intervention: Resistance exercise (3 times a week for 8 weeks)
Number of subjects: 19
Study: 34849546

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d; n=499)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo (n=167)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with baseline 25(OH)D <20 ng/mL
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) with baseline 25(OH)D of 20-30 ng/mL
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 666

Group type: COMPARATOR
Intervention: Vitamin D3 (2000 IU/d) and Placebo
Number of subjects: 666
Study: 34334720

Group type: EXPERIMENTAL
Intervention: CHO hydrogel (90 g·h‐1 of 2:1 glucose‐fructose)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Standard CHO solution (nonhydrogel)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CHO hydrogel
Number of subjects: 11

Group type: COMPARATOR
Intervention: CHO conditions (hydrogel and nonhydrogel)
Number of subjects: 11
Study: 34139464

Group type: EXPERIMENTAL
Intervention: modified lower-protein (mLP) infant formula (1.7 g protein/100 kcal)
Number of subjects: 143

Group type: COMPARATOR
Intervention: control formula (CTRL) (2.1 g protein/100 kcal)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: breast-fed (BF) group
Number of subjects: 143
Study: 33727160

Group type: EXPERIMENTAL
Intervention: Ischemic pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 0
Study: 32448187

Group type: EXPERIMENTAL
Intervention: Family-partnered delirium prevention, detection, and management
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study: 35733283

Group type: EXPERIMENTAL
Intervention: Intravenous acetazolamide (500 mg)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study: 32424868

Group type: EXPERIMENTAL
Intervention: Split high-dose sennoside solutions (1000 mg)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Split-dose polyethylene glycol (4 L)
Number of subjects: 474
Study: 35102477

Group type: EXPERIMENTAL
Intervention: Mini-implant assisted rapid palatal expansion (MARPE)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 35986649

Group type: EXPERIMENTAL
Intervention: Oral nutrition supplements (ONSs) (400 kcal/day) and family-centered nutrition education (once every 2 weeks)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Family-centered nutrition education (control group)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Oral nutrition supplements (ONSs) and family-centered nutrition education
Number of subjects: 201
Study: 34964778

Group type: EXPERIMENTAL
Intervention: ERAS nursing combined with rehabilitation training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 60
Study: 35667837

Group type: EXPERIMENTAL
Intervention: Ponesimod 20 mg
Number of subjects: 464

Group type: COMPARATOR
Intervention: Ponesimod 10 mg
Number of subjects: 464

Group type: COMPARATOR
Intervention: Ponesimod 40 mg
Number of subjects: 464

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study: 36088283

Group type: EXPERIMENTAL
Intervention: Trunk-strengthening exercise group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Walking-balance exercise group
Number of subjects: 64
Study: 33891597

Group type: EXPERIMENTAL
Intervention: Targeted client communication (TCC) via SMS
Number of subjects: 454

Group type: COMPARATOR
Intervention: No TCC (control)
Number of subjects: 454
Study: 34128826

Group type: EXPERIMENTAL
Intervention: Vitamin D3 7000 IU/week
Number of subjects: 192

Group type: COMPARATOR
Intervention: Vitamin D3 2800 IU/week
Number of subjects: 192
Study: 35322798

Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patients (VSPs)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standardized Patients (SPs)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: High Value Care (HVC) didactics
Number of subjects: 66
Study: 32530472

Group type: EXPERIMENTAL
Intervention: Intervention group (n=132)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Control group (n=137)
Number of subjects: 269
Study: 34472598

Group type: EXPERIMENTAL
Intervention: Slow breathing exercise (SBE) performed at home, 30 minutes daily for 12 weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group receiving routine post-PCI care only
Number of subjects: 78
Study: 34162298

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25mcg
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 200/62.5/25mcg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
Number of subjects: 229
Study: 33956209

Group type: EXPERIMENTAL
Intervention: Loop diuretic usage > 40 mg furosemide-equivalent dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loop diuretic usage 1-40 mg furosemide-equivalent dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: No baseline loop diuretic usage
Number of subjects: 0

Group type: COMPARATOR
Intervention: History of hospitalization and/or elevated natriuretic peptides
Number of subjects: 0
Study: 35451469

Group type: EXPERIMENTAL
Intervention: Magnesium (3.2 g daily for 72 hours preoperatively and 1.6 g on the day of surgery)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 200